Related Experiment Videos
Can therapeutic efficacy be predicted from phase I data?
1Sanofi Recherche, Unité de Pharmacologie Clinique, Montpellier, France.
Fundamental & Clinical Pharmacology
|January 1, 1990
Summary
Phase I studies primarily assess new drug safety and pharmacokinetics in healthy volunteers. While they may offer early efficacy signals for some drug classes, definitive therapeutic activity is typically not determined.
Area of Science:
- Pharmacology
- Clinical Trials
Background:
- Phase I studies evaluate new compounds with demonstrated animal activity.
- These studies focus on safety and tolerability in humans.
Purpose of the Study:
- To explore the tolerance and pharmacokinetic features of new drug compounds.
- To identify potential early pharmacological or biological indications of efficacy.
Main Methods:
- Typically involve a single rising dose study followed by a repeated dose study.
- Conducted in a limited number of healthy male volunteers.
Main Results:
- Phase I studies primarily assess drug safety and pharmacokinetics.
- May provide preliminary efficacy signals for specific drug classes like anticancer or antibiotic agents.
- Limited information on therapeutic activity for most drug types, including psychoactive and analgesic compounds.
Conclusions:
- Phase I studies are crucial for initial safety and pharmacokinetic profiling.
- Therapeutic efficacy is generally not ascertainable at this early stage.
- Controlled studies are recommended to investigate potential efficacy signals observed in Phase I.